Gavin Magaha, senior director of innovation at Kalderos and a former Apexus executive, said a recent judicial ruling on the 340B patient definition could increase the number of 340B patients and provider-owned pharmacies.
Genesis Decision Expected to Increase 340B Scripts, Provider-Owned Pharmacies, Says Contractor to Drug Manufacturers and Former Apexus Staffer
The ruling in a recent, high-profile 340B patient definition case will likely result in providers increasing the number of patients [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
